Imagination over iteration

Coming together with backgrounds in biochemistry, chemistry, hardware, molecular biology, photonics, semiconductor chips, and software, our leadership has one thing in common: solving problems no one has thought of yet and disrupting industries to make a global impact on human health.

Leadership

John
 Stark

John
Stark

Chief Executive Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/john-stark-headshot.jpg" title_text="john-stark-headshot" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

John
Stark

Chief Executive Officer

John Stark has served as Quantum-Si’s Chief Executive Officer since November 2020. Prior to joining Quantum-Si, Mr. Stark served as Chief Executive Officer of Celsee, Inc., a single cell analysis solutions provider, from January 2018 to April 2020, when Celsee, Inc. was acquired by Bio-Rad Laboratories, Inc. Mr. Stark previously served as Senior Vice President, Global Commercial Operations, Applied Markets of Fluidigm Corporation, a biotechnology tools provider, from October 2015 to October 2017. Before that, he served as Vice President, Clinical and Applied Markets at Life Technologies Corporation, a global biotechnology company, from October 2011 to October 2015. He also previously served as Senior Director of Sales at Pacific Biosciences of California, Inc., a provider of sequencing platforms, from September 2009 to September 2011, and as District Manager, East Region Industrial Sales, of Affymetrix, Inc., a provider of cellular and genetic analysis products, from April 2001 to January 2007. Mr. Stark earned his M.S. in Bioengineering from Arizona State University. Mr. Stark’s qualifications to serve on the board of directors of New Quantum-Si include his leadership experience in the healthcare industry, as well as his knowledge of Quantum-Si’s business.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Michael P. McKenna

Michael P.
McKenna

President & Chief Operating Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/michael-mckenna-headshot.jpg" title_text="michael-mckenna-headshot" _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Michael P.
McKenna, Ph.D.

President & Chief Operating Officer

Michael P. McKenna, Ph.D. has served as Quantum-Si’s President and Chief Operating Officer since December 2014. Prior to joining Quantum-Si, Dr. McKenna served as Vice President, R&D at Life Technologies Corporation, a global biotechnology company, from August 2011 to July 2014, and as a consultant to Life Technologies from February 2011 to August 2011. Prior to that, Dr. McKenna served as Chief Scientific Officer of Tethys Bioscience, Inc., a diagnostics company, from August 2004 to February 2011, and as Vice President of Curagen Corporation, a biopharmaceutical company, from 1993 to 2003. Dr. McKenna received his B.S. in molecular biology and German from Carnegie Mellon University and his Ph.D. in biology from Yale University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Todd Rearick

Todd
Rearick

Chief Technology Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/05/todd-rearick-headshot.jpg" title_text="todd-rearick-headshot" _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"]

Todd Rearick

Chief Technology Officer

Todd Rearick has served as Quantum-Si's Chief Technology Officer since January 2019. Prior to that Mr. Rearick served as Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and as Systems Engineer from June 2014 to January 2018. Prior to that Mr. Rearick was an Engineering Fellow at Life Technologies from October 2010 to June 2014, and Principal Engineer for Ion Torrent from May 2008 to October 2010. Prior to that Mr. Rearick was a Software Manager at Raindance Technologies from June 2006 to May 2008, and held several positions at Sycamore Networks, a telecommunications equipment manufacturer, from April 1999 to June 2006. Mr. Rearick started his career with the Naval Undersea Warfare Center (NUWC) in New London, Connecticut from 1995 to 1998. Mr. Rearick earned his B.S. in Engineering Science from Penn State University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Matthew Dyer

Matthew
Dyer

Chief Business Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/matt-dryer-headshot.jpg" title_text="matt-dryer-headshot" _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"]

Matthew
Dyer, Ph.D.

Chief Business Officer

Matthew Dyer, Ph.D. has served as Quantum-Si’s Chief Business Officer since December 2020, and served as Quantum-Si’s Chief Product Officer from September 2019 to December 2020 and Head of Product and Marketing from January 2015 to September 2019. Prior to joining Quantum-Si, from April 2014 to January 2015, Dr. Dyer was Head of Cloud and Telemedicine Strategy at the 4Catalyzer medical technology incubator. Prior to that, Dr. Dyer served in various roles at Life Technologies Corporation, a global biotechnology company, including as Associate Director and Group Leader, Informatics Applications from December 2012 to April 2014, Associate Director, Bioinformatics and Community, from February 2012 to December 2012, and Senior Product Manager, Bioinformatics and Community from August 2011 to February 2012. Dr. Dyer received his B.S. in Bioinformatics and B.A. in Russian from Brigham Young University, his Ph.D. in Genetics, Bioinformatics and Computational Biology from Virginia Tech and his M.B.A. from the University of North Carolina.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Claudia Drayton

Claudia
Drayton

Chief Financial Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/QSI-Headshots0290-cropped.jpg" title_text="QSI-Headshots0290-cropped" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Claudia
Drayton

Chief Financial Officer

Claudia Drayton has served as Quantum-Si’s Chief Financial Officer since April 2021. She previously served as Chief Financial Officer of CHF Solutions, Inc., or CHFS, from January 2015 to April 2021. During her tenure as CFO of CHFS, Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company’s commercial expansion. Prior to joining CHFS, Ms. Drayton spent 15 years at Medtronic plc, or Medtronic, a $30 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota’s Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive)

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Christian LaPointe

Christian
LaPointe

General Counsel

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/christian-lapointe-headshot.jpg" title_text="christian-lapointe-headshot" _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"]

Christian
LaPointe, Ph.D.

General Counsel

Christian LaPointe, Ph.D. has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020. Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his Ph.D. in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Results over rules:
Jonathan Rothberg

A prolific inventor and recipient of the Medal of Technology & Innovation under President Obama, Jonathan Rothberg pioneered high speed next generation sequencing as well as semiconductor based sequencing. His next vision: Quantum-Si’s next generation protein sequencing technology for truly accessible proteomics.

As the founder of several groundbreaking companies, Jonathan Rothberg has not only invented new industries, he has disrupted them as well.

Jonathan thrives on harnessing the power of semiconductor technology to create products for improving human health:

Ion Torrent

Ion Torrent disrupted the genomic sequencing industry—where slow and cost prohibitive technology was the norm—to make genomic sequencing more accessible to more brilliant minds.

Butterfly

Butterfly disrupted the ultrasound industry—where products are usually large, bulky, and hard to move around—bringing the portable ultrasound to the market and revolutionizing care in remote areas and regions.

Hyperfine

Hyperfine disrupted conventional MRIs—traditionally driving expensive and time consuming procedures—to put MRI imaging within reach of every patient regardless of location, in any healthcare facility in any country across the globe.

Other Jonathan Rothberg distinctions:

  • White House National Medal of Technology and Innovation, awarded by President Obama
  • Founder of Rothberg Institute for Childhood Diseases
  • The first individual named a World Economic Forum’s Technology Pioneer four separate times
  • Ernst and Young Entrepreneur of the Year
  • The Wall Street Journal’s First Gold Medal for Innovation Recipient